γ‐Vinyl‐GABA (Vigabatrin) in the Therapy of Lennox‐Gastaut Syndrome: An Open Study

@article{Feucht1994VinylGABAI,
  title={$\gamma$‐Vinyl‐GABA (Vigabatrin) in the Therapy of Lennox‐Gastaut Syndrome: An Open Study},
  author={Martha Feucht and S Brantner-Inthaler},
  journal={Epilepsia},
  year={1994},
  volume={35}
}
Summary: The antiepileptic effect of vigabatrin (γ‐vinyl GABA, VGB) in children has been demonstrated in controlled and open studies. According to the literature, results were good to excellent in partial seizures (with and without becoming secondarily generalized) and promising in infantile spasms (IS). In patients with myoclonic epilepsies of early childhood and especially those with Lennox‐Gastaut syndrome (LGS), the effect of VGB has been investigated only to a limited extent and the… Expand

Paper Mentions

Treatment of Lennox-Gastaut Syndrome (LGS).
  • C. Ferrie, Amit Patel
  • Medicine
  • European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2009
TLDR
The evidence supporting the use of available treatments for Lennox-Gastaut Syndrome is not robust and recommendations on how to set appropriate treatment goals, select treatments and minimize polypharmacy are provided. Expand
New antiepileptic drugs in the treatment of Lennox-Gastaut syndrome
TLDR
In this Review, newer antiepileptic drugs (Felbamate, Lamotrigine, Levetiracetam, Topiramate, Rufinamide, Vigabatrin, Zonisamide) in the treatment of Lennox-Gastaut syndrome are discussed. Expand
Pharmacological review of vigabatrin
TLDR
No evidence was recently and clinically given for the use of vigabatrin in treatment of patients with cocaine dependence, but it has a reliable anticonvulsant effect in patients with chronic drugresistant epilepsy, especially patients with severe epilepsy and a history of psychosis. Expand
Treatment of Lennox-Gastaut Syndrome
TLDR
Advances in pharmacological and nonpharmacological approaches to the treatment of Lennox-Gastaut syndrome offer new hope to patients and their families. Expand
New Antiepileptic Drugs for Children: Felbamate, Gabapentin, Lamotrigine, and Vigabatrin
TLDR
Four new antiepileptic drugs have been approved or are under Food and Drug Administration investigation for use in the United States and four of these new drugs—felbamate, gabapentin, lamotrigine, and vigabatrin are reviewed. Expand
Medical management of Lennox-Gastaut syndrome
TLDR
An improvement in the management of Lennox-Gastaut syndrome requires a better understanding of the pathophysiology of this disorder and the development of animal models in which to test new compounds. Expand
Add-On Vigabatrin in Children with Refractory Epilepsy
TLDR
It is concluded that add-on vigabatrin achieved a 4-year long term benefit in at least 40% of children with refractory partial epilepsy, and that the development of tolerance or adverse events were rarely observed in this period. Expand
Anticonvulsant Therapy in Children: An Update
TLDR
The pharmacology, pharmacokinetics, drug interactions, clinical use, adverse effects, and dosage and administration of felbamate, gabapentin, lamotrigine, and vigabatrin are discussed. Expand
A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy
TLDR
This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, which should enable more rational use of these two drugs in the paediatric population with epilepsy. Expand
Newer antiepileptic drugs: advantages and disadvantages
TLDR
Vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine and felbamate, and oxcarbazepine, stiripentol, remacemide, zonisamide and levetiracetam are considered in some detail. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Vigabatrin in the Treatment of Childhood Epilepsies: A Single‐Blind Placebo‐Controlled Study
TLDR
GVG was particularly efficient in cryptogenic partial epilepsy, and nonprogressive myoclonic epilepsy tended to be aggravated, mainly at onset of therapy in mentally retarded patients, but was easily reversed by dose reduction. Expand
Vigabatrin in Pediatric Epilepsy—An Open Study
TLDR
A significant reduction in seizures was noted across the patient population, although patients who were recorded as seizure free at 3 and 6 months did suffer some recurrence of seizures, however, they did so at much lower frequency than recorded at the start of the study. Expand
Vigabatrin in the treatment of epilepsy in children.
TLDR
Vigabatrin appears to be a safe antiepileptic drug that may be effective in the treatment of severe epilepsy in children, with good to excellent results in partial seizures. Expand
Vigabatrin in Childhood Epilepsy
TLDR
It is concluded that vigabatrin is safe and effective in the treatment of refractory epilepsy of various types in children and in patients in whom vigab atrin dose was reduced because of hyperkinesia, a dose increase could be instituted without recurrence of symptoms. Expand
Therapeutic Trial of Vigabatrin in Refractory Infantile Spasms
TLDR
Given the poor prognosis of this type of childhood epilepsy, vigabatrin appears to be a very interesting advance in the management of drug-resistant infantile spasms. Expand
Dose-Response Study of Vigabatrin in Children With Refractory Epilepsy
TLDR
In conclusion, vigabatrin is an effective and well-tolerated therapy in children with refractory epilepsy at the dose of 60 mg/kg/day, and higher doses do not appear to bring any further significant benefit. Expand
Pharmacology and Clinical Pharmacology of Vigabatrin
TLDR
In several trials, however, a small but significant reduction in phenytoin levels has been seen following the addition of vigabatrin to the antiepileptic medication, though it does not appear to be of clinical significance. Expand
Treatment of Infantile Spasms and Lennox‐Gastaut Syndrome with Clonazepam (Rivotril®)
TLDR
Control of spasms for a varying period of time was obtained in 13 infants with West syndrome and in 6 children with Lennox‐Gastaut syndrome, although nearly one‐third of the patients had failed to respond to previous treatment with nitrazepam. Expand
[Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome].
TLDR
In a double-blind crossover trial valproate in association with a phenobarbital dose reduced by about 40% proved to be to a statistically significant degree more active against epileptic seizures than phenobarBital alone. Expand
The treatable epilepsies.
TLDR
The practitioner should try to achieve plasma concentrations that are known to stop seizures (the therapeutic range), because plasma clearance is initially lower in "naive" patients. Expand
...
1
2
3
4
...